We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

62 hedge funds and large institutions have $276M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 9

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

11% more funds holding

Funds holding: 56 → 62 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $288M → $276M (-$12.3M)

Holders
62
Holders Change
+6
Holders Change %
+10.71%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
26
Reduced
9
Closed
10
Calls
$131K
Puts
–
Net Calls
+$131K
Net Calls Change
+$133K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.33M
3
SSA
Schonfeld Strategic Advisors
New York
+$4.08M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.52M
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.99M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$10.2M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$9.2M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
-$1.95M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.72M
5
IC
Ikarian Capital
Texas
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$89M +$424K +43,224 +0.5%
PCM
2
Pentwater Capital Management
Florida
$47.4M – – –
BlackRock
3
BlackRock
New York
$27M +$12.5M +1,278,113 +83%
Millennium Management
4
Millennium Management
New York
$16.9M +$2.84M +289,976 +20%
Vanguard Group
5
Vanguard Group
Pennsylvania
$13.7M +$8.33M +849,245 +144%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$12.2M -$1.72M -175,355 -12%
BC
7
Boxer Capital
California
$11.9M – – –
ACM
8
Aisling Capital Management
New York
$9.96M – – –
PA
9
Perceptive Advisors
New York
$7.52M – – –
State Street
10
State Street
Massachusetts
$4.31M +$2.6M +264,879 +142%
SSA
11
Schonfeld Strategic Advisors
New York
$3.97M +$4.08M +415,692 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.85M +$1.86M +189,886 +89%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$3.67M +$3.52M +359,002 +1,391%
JP Morgan Chase
14
JP Morgan Chase
New York
$2.97M +$2.99M +304,917 +5,129%
RSCM
15
Rock Springs Capital Management
Maryland
$2.77M – – –
ASN
16
Advisory Services Network
Georgia
$2.45M +$2.52M +256,771 New
PVI
17
Pura Vida Investments
New York
$2.26M +$2.32M +236,311 New
Northern Trust
18
Northern Trust
Illinois
$1.58M +$31.7K +3,230 +2%
Charles Schwab
19
Charles Schwab
California
$1.35M +$510K +52,038 +58%
Citadel Advisors
20
Citadel Advisors
Florida
$1.3M +$1.33M +136,058 New
UBS Group
21
UBS Group
Switzerland
$1.13M +$95.2K +9,706 +9%
VOYA Investment Management
22
VOYA Investment Management
Georgia
$1.12M -$1.34M -136,124 -54%
N
23
Nuveen
North Carolina
$945K +$640K +65,203 +193%
IC
24
Ikarian Capital
Texas
$820K -$1.62M -165,000 -66%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$603K +$329K +33,519 +113%
1
2 3

PSTX Hedge Fund Activity: Q1 2021 in Review

62 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2021, worth a combined $276M — down 4.3% from $288M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new PSTX positions and 10 closed out — a net gain of 6 holders — while 26 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $12.5M. The largest seller was Vivo Capital, exiting entirely with an estimated $10.2M sold.

  • 62 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2021, up from 56 in Q4 2020.
  • Funds reported $276M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2021, down 4.3% quarter-over-quarter.
  • 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2021 and 10 closed out, a net change of +6 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2021 was BlackRock, an estimated $12.5M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2021 was Vivo Capital, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2021.